New drug duo targets hard-to-treat cancers in early trial
NCT ID NCT07512583
First seen Apr 06, 2026 · Last updated May 08, 2026 · Updated 4 times
Summary
This study tests two experimental drugs, TQB2930 and TQB2102, given together to people with advanced solid tumors that have a protein called HER2. The goal is to find the safest and most effective dose and see if the combination can shrink tumors. About 178 adults aged 18 to 75 with HER2-positive advanced cancers will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.